Drug profile

The FDA adverse-event record for Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
53.8%
death-coded share
Cattle
most-reported species
5
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
7
Deaths Reported
53.8%
Death Rate

Active Ingredients

Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid

Administration Routes

SubcutaneousUnknownIntramuscular

Species Affected

Cattle 13

Most Affected Breeds

Cattle (other) 5
Crossbred Bovine/Cattle 3
Cattle (unknown) 3
Aberdeen Angus 2

Most Reported Reactions

Death 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Recumbency 3
Nasal discharge 3
Abortion 3
Death by euthanasia 3
Lack of efficacy - NOS 2
NT - Abnormal necropsy finding NOS 2
Other abnormal test result NOS 2
Sinusitis 1
Malaise 1
Partial lack of efficacy 1

Outcome Breakdown

Died
7 (38.9%)
Recovered/Normal
5 (27.8%)
Outcome Unknown
3 (16.7%)
Euthanized
2 (11.1%)
Ongoing
1 (5.6%)

Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid Adverse Event Insights

13 reports name Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid; 7 recorded a death outcome (53.8% of reported events, not a population-level mortality rate). Active ingredient: Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid. Administration routes: Subcutaneous, Unknown, Intramuscular.

By species: Cattle (13 reports). By breed: Cattle (other) (5), Crossbred Bovine/Cattle (3), Cattle (unknown) (3).

Leading clinical signs: Death (5), Lethargy (see also Central nervous system depression in 'Neurological') (5), Recumbency (3), Nasal discharge (3). Outcome, 18 coded reports: Died leads at 38.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.